VivoSeq
Other

Bleeding

3

Pipeline Programs

15

Active Trials

10

Companies Involved

Bleeding is an early-stage landscape with 3 programs across 10 companies. The most active players are Bayer, Octapharma, Amring. 1 program is in Phase 3.

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

25/100

Mech. Concentration

100/100

Completion Rate

83/100

Attrition Rate

11/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Phase 1
No programs
Phase 2
No programs
Approved
No programs

Trial Status

83

clinical trials

Completed45 · 54%
Unknown status14 · 17%
Recruiting11 · 13%
Terminated8 · 10%
Not yet recruiting3 · 4%
Active, not recruiting1 · 1%
Other1 · 1%

Trial Activity

83 trials

HOST - DAPT Duration According the Bleeding Risk
Active, not recruiting·SSeoul National University Hospital·Phase 4·NCT05631769·4,900 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)